Dilated Cardiomyopathy

📋 Key Information Summary

📋

Definition: Dilated cardiomyopathy (DCM) is characterised by left ventricular dilatation and systolic dysfunction (LVEF ≤40%) in the absence of abnormal loading conditions or coronary artery disease sufficient to explain the degree of impairment.
Prevalence: Estimated prevalence of 1:250–1:500 in Australia; DCM accounts for approximately 30–40% of all non-ischaemic heart failure presentations and is the leading indication for cardiac transplantation.
Ischaemic vs non-ischaemic: Coronary angiography (CT or invasive) is mandatory in all newly diagnosed DCM patients aged >40 years or with cardiovascular risk factors to exclude ischaemic aetiology — this distinction drives both prognosis and management.
Genetic aetiology: Up to 30–50% of idiopathic DCM is genetic; TTN (titin) truncating variants account for ~25% of familial cases. Genetic testing should be offered to all patients with a family history of DCM, sudden cardiac death, or early-onset heart failure.
Myocardial biopsy: Endomyocardial biopsy (EMB) is indicated when acute myocarditis is suspected (acute heart failure with recent viral illness, new LVEF <45%, elevated troponin), giant cell myocarditis, eosinophilic myocarditis, or cardiac sarcoidosis is on the differential.
GDMT pillars: Guideline-directed medical therapy comprises ACEi/ARB/ARNI, beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor (dapagliflozin or empagliflozin) — all four should be initiated and uptitrated to maximum tolerated doses.
ICD candidacy: Primary prevention ICD (implantable cardioverter-defibrillator) should be considered after ≥3 months of optimal GDMT if LVEF remains ≤35% (NYHA II–III); secondary prevention ICD for survivors of cardiac arrest or sustained VT.
Inflammatory DCM: Immunosuppression (prednisolone ± azathioprine) may be considered in biopsy-proven inflammatory DCM; empiric immunosuppression without biopsy confirmation is NOT recommended.
Alcohol and toxic DCM: Complete alcohol abstinence is essential in alcohol-related DCM — partial recovery of LVEF is common with sustained abstinence. Anthracycline-induced DCM requires cardiotoxicity surveillance during and after chemotherapy.
Family screening: First-degree relatives of all DCM patients should undergo clinical screening with ECG and transthoracic echocardiography, ideally with genetic counselling if a pathogenic variant is identified.
Advanced therapies: Referral for heart transplant assessment and/or LVAD evaluation should be considered early when patients demonstrate persistent NYHA III–IV symptoms, declining LVEF despite optimal GDMT, recurrent hospitalisations, or INTERMACS profiles ≤4.
ATSI populations: Aboriginal and Torres Strait Islander Australians have a 2–3-fold higher burden of heart failure and cardiomyopathy; rheumatic heart disease remains a significant cause of secondary DCM in remote communities. Culturally safe screening and early referral are essential.
Monitoring: Serial echocardiography at 3–6 months after treatment initiation, then annually. Serial NT-proBNP monitoring helps guide therapy. Multidisciplinary heart failure management programs reduce readmissions and mortality.

Introduction & Australian Epidemiology

Dilated cardiomyopathy (DCM) is a myocardial disorder defined by ventricular chamber enlargement and systolic impairment that is not explained by abnormal loading conditions (hypertension, valve disease) or coronary artery disease sufficient to account for the global dysfunction. The hallmark haemodynamic finding is a reduced left ventricular ejection fraction (LVEF ≤40%), which underlies the clinical syndrome of heart failure with reduced ejection fraction (HFrEF).

DCM is the most common cardiomyopathy globally and the most frequent reason for cardiac transplantation worldwide. The aetiology is heterogeneous — genetic, infectious, toxic, autoimmune, and idiopathic mechanisms all contribute — making systematic diagnostic evaluation essential.

Australian Burden of Disease

Prevalence: Approximately 1 in 250 to 1 in 500 Australians carry a diagnosis of DCM, though subclinical disease is likely under-detected. The Australian Institute of Health and Welfare (AIHW) reports cardiomyopathies as a significant contributor to the >60,000 annual heart failure hospitalisations nationally.
Incidence: Population-based Australian data suggest an incidence of approximately 5–8 per 100,000 person-years for new-onset DCM, with higher rates in males and those of lower socioeconomic status.
Heart failure burden: Heart failure affects an estimated 480,000 Australians; DCM underlies 30–40% of HFrEF cases in Australian tertiary centres. The condition accounts for approximately 2.5% of all hospitalisations in those aged >65 years.
Transplant data: The Australian and New Zealand Organ Donation Registry (ANZOD) and the Australian & New Zealand Cardiothoracic Transplant Registry report DCM as the leading primary diagnosis in ~45% of adult heart transplant recipients.
Indigenous Australians: Aboriginal and Torres Strait Islander Australians carry a 2–3-fold excess burden of heart failure, with rheumatic heart disease (RHD) remaining an important cause of secondary cardiomyopathy in remote Northern Territory and Western Australian communities.
Economic impact: Heart failure costs the Australian healthcare system approximately $2.7 billion annually; DCM-related costs include ongoing pharmacotherapy (PBS expenditure), device implantation, hospital readmissions, and advanced therapies.

⚠️

Key Australian context: The 2024 Australian Chronic Heart Failure Clinical Care Standard (ACSQHC) emphasises timely diagnosis, early GDMT initiation, multidisciplinary care, and transition to community-based heart failure management programs — all directly applicable to DCM management.

Etiology & Diagnosis

A systematic diagnostic approach is essential because the aetiology of DCM influences prognosis, treatment decisions (particularly immunosuppression and device therapy), and the need for family screening. The initial workup must distinguish ischaemic from non-ischaemic DCM and identify potentially reversible or treatable causes.

Ischaemic vs Non-Ischaemic Differentiation

Differentiating ischaemic from non-ischaemic cardiomyopathy is a critical first step because the management pathways, eligibility for revascularisation, and prognosis differ substantially. In ischaemic cardiomyopathy, regional wall motion abnormalities correspond to coronary territories, whereas non-ischaemic DCM typically demonstrates global hypokinesis with or without mid-wall fibrosis.

Feature	Ischaemic DCM	Non-Ischaemic DCM
Coronary anatomy	Significant epicardial CAD (≥70% stenosis) or prior MI	Normal or non-obstructive coronaries
Wall motion	Regional — corresponding to coronary territory	Global hypokinesis ± regional mid-wall fibrosis pattern
LV morphology	May be segmental dilatation with aneurysm	Concentric global dilatation
History	Prior MI, angina, PCI/CABG	Variable — may be familial, post-viral, toxic, idiopathic
CMR pattern	Subendocardial/transmural LGE in coronary territory	Mid-wall fibrosis (non-territorial LGE), or diffuse oedema (myocarditis)
Prognosis	Worse — potential benefit from revascularisation	Generally better 5-year survival if idiopathic

🚨

Mandatory coronary assessment: All patients with newly diagnosed DCM aged >40 years, or younger patients with ≥2 cardiovascular risk factors, must undergo coronary angiography (CT coronary angiography or invasive) to exclude significant ischaemic disease. This is particularly important as up to 30% of "idiopathic DCM" cases in older patients have unrecognised ischaemic aetiology.

Comprehensive Aetiological Workup

After excluding coronary artery disease, the following evaluation should be performed to identify reversible or treatable causes:

Category	Specific Causes	Key Investigations
Toxic / drug-related	Alcohol (≥80 g/day for >5 years), anthracyclines (doxorubicin, epirubicin), trastuzumab, cocaine, methamphetamine, hydroxychloroquine	Detailed substance and chemotherapy history; urine drug screen
Infectious / inflammatory	Viral myocarditis (Coxsackievirus, parvovirus B19, HHV-6, SARS-CoV-2), giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis, Chagas disease, HIV	CMR (oedema, LGE pattern), EMB if indicated; serology (HIV, Trypanosoma); FDG-PET for sarcoidosis
Endocrine / metabolic	Hypothyroidism, hyperthyroidism, phaeochromocytoma, acromegaly, thiamine deficiency (beriberi), carnitine deficiency, iron overload (haemochromatosis)	TFTs, 24-hr urinary catecholamines, serum iron studies, echocardiographic iron assessment
Autoimmune / systemic	Systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, sarcoidosis, vasculitis, eosinophilic granulomatosis with polyangiitis (EGPA)	ANA, anti-dsDNA, RF, anti-CCP, ACE level, ESR, CRP, eosinophil count
Infiltrative / storage	Amyloidosis (AL and ATTR), Fabry disease, haemochromatosis	Serum free light chains, technetium-99m pyrophosphate scintigraphy (ATTR), alpha-galactosidase A activity, genetic testing
Peripartum	Peripartum cardiomyopathy (last month of pregnancy to 5 months postpartum)	Echocardiography in patients with new heart failure symptoms peri/postpartum
Arrhythmia-mediated	Chronic tachycardia (persistent AF, incessant SVT, permanent junctional reciprocating tachycardia)	ECG, Holter; rate control or ablation may reverse DCM
Genetic / familial	TTN, LMNA, MYH7, MYBPC3, SCN5A, RBM20, FLNC, DSP, PLN, BAG3, DES variants	Genetic testing panel (see Genetic Testing section)
Rheumatic heart disease	Chronic rheumatic carditis with progressive ventricular dilatation — particularly relevant in ATSI communities	Echocardiography (valvular involvement), ASO titre, ESR/CRP

Diagnostic Imaging Modalities

Essential Transthoracic Echocardiography (TTE) First-line investigation. LV dilatation (LVEDD >58 mm or >32 mm/m²), LVEF ≤40%, global or regional wall motion abnormalities, MR assessment, LA size, RV function, and estimation of filling pressures. Serial TTE at baseline, 3–6 months, and annually thereafter. MBS item 55118.

Available Cardiac Magnetic Resonance Imaging (CMR) Gold standard for tissue characterisation. Late gadolinium enhancement (LGE) pattern helps distinguish ischaemic (subendocardial/transmural) from non-ischaemic (mid-wall fibrosis, epicardial for myocarditis). T1/T2 mapping detects diffuse fibrosis and oedema. Available at major Australian tertiary centres. MBS item 63484 (where eligible).

Available Coronary Angiography (CT or invasive) CT coronary angiography (MBS item 57360) for low-to-intermediate risk; invasive coronary angiography (MBS item 38218) when revascularisation is likely or CT is inconclusive. Mandatory in patients >40 years.

Referral Endomyocardial Biopsy (EMB) Performed at specialised centres only. Indicated for suspected acute myocarditis with haemodynamic compromise, giant cell myocarditis (high mortality without immunosuppression), eosinophilic myocarditis, cardiac transplant rejection monitoring, and suspected cardiac amyloidosis. Sensitivity is limited by sampling error (~50–60% for myocarditis).

Available FDG-PET / CT (Cardiac Sarcoidosis) FDG-PET/CT is the preferred modality for diagnosing cardiac sarcoidosis, demonstrating active inflammation (FDG uptake) and assessing burden of disease. Available at major PET centres nationally. MBS item 61406 (where eligible under Medicare criteria).

Myocardial Biopsy — Indications and Utility

Endomyocardial biopsy is an invasive procedure with a complication rate of <1% (perforation, tamponade, arrhythmia). Its utility is highest when histological diagnosis would change management. The 2023 ESC position statement on EMB recommends the following indications:

Class I — Definite

Strong indications for EMB

Acute heart failure with suspected giant cell myocarditis (rapid deterioration); suspected cardiac amyloidosis for subtyping (AL vs ATTR); suspected eosinophilic myocarditis; cardiac transplant rejection monitoring.

Proceed without delay — emergent if haemodynamically unstable

Class IIa — Reasonable

Consider EMB

New-onset heart failure with LVEF <45%, elevated troponin, and recent viral illness; suspected cardiac sarcoidosis when CMR is inconclusive; new-onset heart failure in the setting of immune checkpoint inhibitor therapy.

Discuss with cardiomyopathy specialist within 48 hours

Class III — Not indicated

Routine EMB not recommended

Chronic stable DCM of >3 months' duration with no change in clinical trajectory; idiopathic DCM after negative comprehensive non-invasive workup.

Manage with GDMT; biopsy only if new clinical features emerge

Biomarkers in Diagnosis

Biomarker	Role in DCM	Australian Availability / MBS
NT-proBNP / BNP	Diagnosis of heart failure (rule-out); prognostic marker; guides therapy (target NT-proBNP <1000 pg/mL); serial monitoring	Widely available. MBS item 66407 (BNP). Bulk-billed at most pathology providers.
High-sensitivity troponin	Elevated in myocarditis, acute decompensation, and ongoing myocardial injury; helps select patients for EMB	Standard across all Australian hospitals.
Serum iron studies	Haemochromatosis screening (ferritin, transferrin saturation); iron deficiency assessment (ferritin <100 or 100–299 with TSAT <20%) — intravenous iron improves symptoms in HFrEF	Standard pathology. MBS item 66571.
TFTs (TSH, fT4, fT3)	Exclude thyroid dysfunction — reversible cause of DCM	Standard pathology.
Serum free light chains + SPEP/UPEP	Screen for AL amyloidosis in all patients with suspected cardiac amyloidosis	Available at all major pathology providers.
hs-CRP / ESR	Non-specific inflammatory markers; elevated in myocarditis, sarcoidosis, autoimmune aetiologies	Standard pathology.

Treatment Protocols

Management of DCM follows the principles of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), with additional targeted interventions for specific aetiologies. The 2024 Australian Chronic Heart Failure Clinical Care Standard and Therapeutic Guidelines (eTG) recommend a structured approach to GDMT initiation and uptitration.

Guideline-Directed Medical Therapy (GDMT) — The Four Pillars

✅

Quadruple therapy mandate: All four pillars of GDMT should be initiated at low doses and uptitrated to maximum tolerated doses in every DCM patient with LVEF ≤40%. Early sequential initiation (within the first 4 weeks) is recommended rather than waiting for full uptitration of one agent before starting the next. Up-titrate every 2–4 weeks as tolerated.

💊

Sacubitril/Valsartan (Entresto®)

Novartis · ARNI · First-line RAAS inhibitor

Adult dose Start 49/51 mg PO BD; titrate to 97/103 mg PO BD. If not previously on ACEi/ARB, start 24/26 mg BD. Must wait 36 hours after last ACEi dose.

Renal adjustment eGFR 30–60 mL/min: start 24/26 mg BD. Avoid if eGFR <20 mL/min. No dialysis data.

Key adverse effects Hypotension, hyperkalaemia, angioedema (rare). Contraindicated with aliskiren in diabetics.

PBS status ✔ PBS Authority Required — for chronic heart failure with LVEF ≤40%.

💊

Enalapril / Perindopril

ACEi alternative if ARNI not tolerated

Adult dose Enalapril 2.5 mg PO BD, titrate to 10–20 mg BD. Perindopril 2 mg PO daily, titrate to 8–10 mg daily.

Renal adjustment Start at lowest dose if eGFR <30 mL/min; monitor K⁺ and creatinine at 1–2 weeks.

PBS status ✔ PBS General Benefit

💊

Carvedilol / Metoprolol Succinate / Bisoprolol

Evidence-based beta-blockers for HFrEF

Carvedilol dose Start 3.125 mg PO BD; titrate every 2 weeks to target 25 mg BD (≥85 kg: 50 mg BD).

Metoprolol succinate dose Start 23.75–47.5 mg PO daily; titrate to 190 mg daily.

Bisoprolol dose Start 1.25 mg PO daily; titrate to 10 mg daily.

Renal adjustment No significant renal adjustment required.

PBS status ✔ PBS General Benefit

💊

Spironolactone / Eplerenone

Mineralocorticoid Receptor Antagonists (MRA)

Spironolactone dose Start 12.5–25 mg PO daily; titrate to 50 mg daily.

Eplerenone dose Start 25 mg PO daily; titrate to 50 mg daily. Less gynaecomastia risk than spironolactone.

Renal adjustment Avoid if eGFR <30 mL/min or K⁺ >5.0 mmol/L. Monitor K⁺ at 1 week, 4 weeks, and 3-monthly.

PBS status ✔ PBS General Benefit

💊

Dapagliflozin (Forxiga®) / Empagliflozin (Jardiance®)

SGLT2 inhibitors — fourth pillar of GDMT

Dapagliflozin dose 10 mg PO once daily (with or without food). No titration needed.

Empagliflozin dose 10 mg PO once daily.

Renal adjustment Can initiate if eGFR ≥20 mL/min for heart failure indication. Continue if eGFR falls below 20. Dapagliflozin PBS authority requires eGFR ≥25 at initiation.

Key adverse effects Genital mycotic infections, volume depletion, DKA risk (hold peri-operatively), Fournier's gangrene (rare).

PBS status ⚠ PBS Authority Required — for HFrEF with LVEF ≤40%.

Additional Pharmacotherapy

💊

Hydralazine + Isosorbide Dinitrate (BiDil® components)

Vasodilator combination — for ACEi/ARB/ARNI intolerance

Adult dose Hydralazine 37.5 mg + isosorbide dinitrate 20 mg PO TDS (fixed-dose combination). Alternatively, isosorbide mononitrate 60 mg daily + hydralazine 75 mg TDS.

Indication Patients who cannot tolerate ACEi/ARB/ARNI (e.g., recurrent angioedema, severe renal impairment). Consider specifically in self-identified Black patients (A-HeFT data) — though less relevant in Australian population, it remains an option for intolerance.

PBS status ✔ PBS General Benefit (individual components)

💊

Ivabradine (Coralan®)

If-channel inhibitor — sinus rate control

Adult dose Start 5 mg PO BD; titrate to 7.5 mg BD if resting HR remains ≥70 bpm despite maximally tolerated beta-blocker.

Indication Symptomatic HFrEF (NYHA II–III), sinus rhythm, resting HR ≥70 bpm despite maximally tolerated beta-blocker, OR beta-blocker contraindicated/not tolerated.

PBS status ⚠ PBS Authority Required

💊

Iron replacement (Ferric carboxymaltose — Ferinject®)

IV iron for iron deficiency in HFrEF

Dose Iron deficit calculated by Ganzoni formula. Single-dose infusions of up to 1000 mg IV over ≥15 minutes. Repeat as needed to achieve ferritin ≥100 and TSAT ≥20%.

Indication Iron deficiency (ferritin <100, or ferritin 100–299 with TSAT <20%) in symptomatic HFrEF, regardless of anaemia status. Evidence from AFFIRM-AHF and IRONMAN trials.

PBS status ⚠ PBS Authority Required — for iron deficiency in chronic heart failure.

Device Therapy — ICD and CRT

⚠️

Critical timing: ICD implantation for primary prevention should only be performed after ≥3 months of optimised GDMT, as LVEF may improve significantly with medical therapy alone, potentially rendering the patient ineligible. Repeat echocardiography at 3–6 months before device decision-making.

Device	Indication	Criteria
ICD — Primary Prevention	Reduce sudden cardiac death in high-risk DCM patients	LVEF ≤35% after ≥3 months optimal GDMT; NYHA II–III; life expectancy >1 year with good functional status. Consider if LVEF ≤30% regardless of NYHA class.
ICD — Secondary Prevention	Survivors of cardiac arrest or sustained VT	Cardiac arrest survivor; sustained VT with haemodynamic compromise; syncope with inducible VT at EP study.
CRT (CRT-D or CRT-P)	Cardiac resynchronisation for dyssynchrony-related worsening	LVEF ≤35%, LBBB with QRS ≥150 ms, NYHA II–IV despite optimal GDMT, sinus rhythm. CRT-D preferred if also ICD-indicated. Non-LBBB: QRS ≥150 ms considered, weaker evidence.

Immunosuppression in Inflammatory DCM

Immunosuppressive therapy should be reserved for biopsy-proven inflammatory aetiologies and is not routinely recommended for all DCM patients.

Condition	Immunosuppressive Regimen	Evidence & Notes
Giant cell myocarditis	Methylprednisolone 1g IV daily × 3 days → prednisolone 1 mg/kg/day PO, wean over 6–12 months. Add cyclosporine 3–5 mg/kg/day or azathioprine 2 mg/kg/day.	Mandatory — untreated mortality >90% at 1 year. Early transplant referral simultaneously.
Eosinophilic myocarditis	Methylprednisolone 500–1000 mg IV daily × 3 days → prednisolone 1 mg/kg/day. Add mepolizumab 300 mg SC 4-weekly for EGPA-related cases.	Identify and treat underlying cause (hypereosinophilic syndrome, EGPA, drug reaction).
Cardiac sarcoidosis	Prednisolone 0.5–1 mg/kg/day for 4–8 weeks, then slow taper over 6–12 months. Add methotrexate 10–20 mg/week as steroid-sparing agent if relapsing.	FDG-PET guides treatment initiation and response. Multidisciplinary with respiratory/sarcoidosis team.
Lymphocytic myocarditis (viral)	Immunosuppression NOT recommended unless viral PCR negative on biopsy. If autoimmune-negative, viral-positive: consider antivirals. If virus-negative, inflammation-positive: prednisolone 1 mg/kg/day + azathioprine.	TIMIC trial showed benefit of immunosuppression in virus-negative, inflammation-positive lymphocytic myocarditis.
Immune checkpoint inhibitor (ICI) myocarditis	Hold ICI immediately. Methylprednisolone 1g IV daily for 3–5 days → prednisolone 1–2 mg/kg/day taper over ≥6 weeks. Add mycophenolate or infliximab for steroid-refractory cases.	High mortality — urgent cardiology-oncology MDT. Re-challenge with ICI is generally contraindicated after grade ≥3 myocarditis.

Alcohol Cessation in Alcoholic DCM

✅

Recovery potential: Complete alcohol abstinence can lead to significant LVEF improvement (absolute increase of 10–15% or more) over 3–6 months in alcohol-related DCM. Even patients with severe LV dysfunction may achieve near-normalisation of LVEF with sustained abstinence, potentially avoiding device implantation. This is one of the most impactful reversible causes of DCM.

Threshold: Significant risk of alcoholic cardiomyopathy with ≥80 g alcohol/day (approximately 8 standard drinks/day) for ≥5 years, though lower cumulative exposure may be sufficient in some individuals.
Counselling: All patients with suspected alcohol-related DCM should receive structured alcohol counselling and referral to addiction medicine services. The AUDIT-C screening tool should be administered.
Pharmacological support: Naltrexone (50 mg PO daily) or acamprosate (666 mg PO TDS) for alcohol use disorder — both PBS-listed for this indication. Thiamine supplementation (100 mg PO daily) should be co-prescribed.
Monitoring: Repeat echocardiography at 3 and 6 months after alcohol cessation to assess for recovery. If LVEF improves to >35%, reassess device candidacy.
Relapse: Relapse to harmful drinking predicts recurrent LV deterioration. Integrated cardiac and addiction services are essential. Australian data suggest that only ~50% of patients achieve sustained abstinence.

Peripartum Cardiomyopathy

Defined as heart failure secondary to LV systolic dysfunction (LVEF ≤45%) occurring in the last month of pregnancy or within 5 months of delivery, with no other identifiable cause.
GDMT principles apply, but ACEi/ARB/ARNI are contraindicated during pregnancy — use hydralazine + nitrates + carvedilol during pregnancy. Sacubitril/valsartan and SGLT2 inhibitors are also contraindicated in pregnancy.
Bromocriptine (2.5 mg PO BD for 2 weeks, then 2.5 mg daily for 4 weeks) may be considered to inhibit prolactin-driven pathophysiology — supported by small trials. Discuss with cardiologist and obstetrician.
Approximately 50% of patients recover LVEF to ≥50% within 6–12 months; those who do not should be reclassified as chronic DCM and managed accordingly.

Anthracycline Cardiotoxicity Prevention and Management

Prevention

Baseline echocardiography before initiation of anthracycline therapy
Serial echocardiography during treatment (every 2–4 cycles for high-risk regimens)
Cumulative dose limits: doxorubicin 450–550 mg/m²; epirubicin 900–1000 mg/m²
Dexrazoxane (cardioprotectant) for patients receiving high cumulative doses
Consider liposomal formulations (Caelyx®) for higher-risk patients
Global longitudinal strain (GLS) on speckle tracking echocardiography — early detection of subclinical cardiotoxicity (>15% relative reduction from baseline)

Management if Cardiotoxicity Develops

Initiate GDMT (ACEi/ARB/ARNI + beta-blocker) immediately upon detection of LVEF decline
Cardiology-oncology MDT discussion — risk-benefit analysis of continuing chemotherapy
Trastuzumab-related cardiomyopathy is typically reversible (unlike anthracycline toxicity) — recovery of LVEF occurs in >80% after drug cessation
Long-term cardiac follow-up for all anthracycline-exposed patients — survivorship care plans per ACSQHC standards

Genetic Testing & Counseling

Genetic factors are increasingly recognised as major contributors to DCM aetiology. Approximately 30–50% of "idiopathic" DCM cases have a genetic basis when systematic testing and family screening are performed. Genetic diagnosis enables targeted family screening, informs prognosis (particularly LMNA variants), guides device decisions, and enables reproductive counselling.

When to Refer for Genetic Testing

1

Family history positive

≥1 first- or second-degree relative with confirmed DCM, unexplained sudden cardiac death <50 years, or early-onset heart failure <40 years.

2

Young-onset DCM

DCM diagnosed <40 years of age without identified acquired cause (alcohol, hypertension, myocarditis).

3

Conduction disease + DCM

DCM with atrioventricular block, atrial fibrillation, or ventricular arrhythmias — consider LMNA, SCN5A, DES, FLNC variants.

4

Idiopathic DCM

All patients with truly idiopathic DCM after comprehensive negative workup should be offered genetic counselling and testing.

5

Concurrent skeletal myopathy

DCM with elevated CK, proximal muscle weakness, or muscle biopsy abnormalities — consider dystrophinopathies, laminopathies, desminopathies.

Key Genes in DCM

Gene	Protein / Function	Frequency in Familial DCM	Key Clinical Features	Inheritance
TTN	Titin — sarcomere structural protein	~25% of familial DCM	Most common genetic cause. Truncating variants (TTNtv) predominantly affect A-band. Generally reduced penetrance (~10–20% by age 40). Good prognosis on GDMT.	AD
LMNA	Lamin A/C — nuclear envelope	~6–8%	High-risk gene — conduction disease (AV block), atrial fibrillation, ventricular arrhythmias, aggressive phenotype. Lower threshold for ICD implantation. Consider early EP study.	AD
MYH7	β-myosin heavy chain	~4–5%	Overlap with hypertrophic cardiomyopathy mutations. Can present with isolated DCM.	AD
MYBPC3	Myosin-binding protein C	~3–4%	Usually associated with HCM; DCM phenotype less common.	AD
FLNC	Filamin C — Z-disc	~3–5%	Associated with ventricular arrhythmias and fibrosis. Sudden death risk — consider ICD at earlier stage.	AD
PLN	Phospholamban — calcium handling	~1–2%	Aggressive phenotype; risk of end-stage HF and sudden death. Founder variant p.Arg14del particularly malignant.	AD
RBM20	RNA-binding motif protein 20	~2–3%	Very aggressive early-onset DCM, high arrhythmia burden, risk of LV thrombus. Early transplant consideration.	AD
SCN5A	Cardiac sodium channel	~2%	Overlap with Brugada syndrome, progressive cardiac conduction defect. DCM + arrhythmia phenotype.	AD
DES	Desmin — intermediate filament	~1–2%	DCM + skeletal myopathy. May have elevated CK. Progressive conduction disease.	AD/AR
DSP / DSG2 / PKP2	Desmosomal proteins	~2–3%	Arrhythmogenic cardiomyopathy — overlap phenotype with DCM. Arrhythmias, fibrofatty replacement. May mimic DCM on echo.	AD
DMD	Dystrophin	X-linked	Duchenne/Becker muscular dystrophy. DCM may be presenting feature before overt myopathy. Female carriers may develop DCM in adulthood.	X-linked

Interpreting Genetic Test Results

⚠️

Variant interpretation complexity: Not all identified genetic variants are disease-causing. Genetic results must be interpreted by a clinical geneticist or genetic counsellor experienced in cardiomyopathies. The ACMG/AMP classification (pathogenic, likely pathogenic, variant of uncertain significance [VUS], likely benign, benign) determines clinical actionability. A VUS should NOT be used for family cascade screening or clinical decision-making.

Result	Clinical Action	Family Implications
Pathogenic / Likely Pathogenic	Confirmatory for genetic DCM. Guide prognosis (LMNA, PLN, RBM20 = high-risk). Influence ICD threshold. Cascade testing of first-degree relatives.	50% risk for each offspring. Cascade screening with variant-specific testing. At-risk relatives undergo ECG + echo even if genetic test negative (reduced penetrance).
Variant of Uncertain Significance (VUS)	Do NOT use for clinical decision-making. Continue clinical surveillance as if no genetic result. May be reclassified over time as databases grow.	NOT suitable for cascade screening. Re-contact every 1–2 years for reclassification updates.
Negative (no pathogenic variant identified)	Does not exclude genetic aetiology (up to 70% of familial DCM remains genetically elusive with current panels). Clinical family screening still recommended.	First-degree relatives should still undergo clinical screening (ECG + echo) given the high rate of genetically unsolved cases.

Family Cascade Screening Protocol

1

Genetic counselling

Refer all first-degree relatives of DCM patients to genetic counselling. Australian Genetic Heart Disease Registry can facilitate testing at accredited laboratories (e.g., Sonic Genetics, PathWest).

2

Variant-specific testing

If a pathogenic variant is identified in the proband, offer targeted testing to at-risk family members. Test only the specific variant — not full panel.

3

Clinical surveillance for carriers

Variant carriers: ECG + TTE at baseline, then every 1–3 years (annually if LMNA, PLN, or RBM20). CMR if borderline echo findings. Intensive screening in adolescents/young adults planning competitive sport.

4

Non-carrier reassurance

Family members who test negative for the known familial variant can generally be discharged from cardiac surveillance — they have the same risk as the general population. Provide formal written confirmation.

5

Psychosocial support

Genetic diagnosis impacts family dynamics, insurance, and reproductive decisions. Offer psychological support and discuss Australian Genetic Discrimination protections under the Disability Discrimination Act 1992. Refer to Cardiac Genetic Counselling services available at most state genetics services.

Australian Genetic Testing Access

Service	Details
State Clinical Genetics Services	Publicly funded genetic counselling and testing for hereditary cardiomyopathies. Available in all states/territories. Wait times vary (2–6 months). Refer through cardiologist or GP.
Sonic Genetics / PathWest / VCGS	Cardiomyopathy gene panels (40–100+ genes). Turnaround 6–12 weeks. May be bulk-billed when referred through genetics service; private testing ~$500–800.
Australian Genetic Heart Disease Registry	Research registry at Victor Chang Cardiac Research Institute. Facilitates research participation and family contact for genetic studies.
MBS Medicare	No dedicated MBS item for cardiomyopathy genetic testing currently. Testing is funded through state hospital genetics services or via research pathways.

Reproductive Counselling

Autosomal dominant DCM confers a 50% risk of inheritance for each child. Preimplantation genetic testing (PGT-M) is available in Australia through accredited IVF centres for known pathogenic variants.
Discuss reproductive options including natural conception with prenatal testing, PGT-M, donor gametes, and adoption.
Women with DCM (particularly LMNA, RBM20, PLN) must be counselled about pregnancy risks — haemodynamic changes in pregnancy increase risk of decompensation. Multidisciplinary cardio-obstetric care at a tertiary centre is essential.

Prognosis & Monitoring

Prognosis in DCM is highly variable and depends on aetiology, genetic substrate, response to GDMT, and the presence of adverse risk features. Serial monitoring is essential to guide therapeutic escalation and timely referral for advanced heart failure therapies.

Risk Stratification

Low Risk

Favourable prognosis

Idiopathic or TTNtv-related DCM; LVEF >30%; NYHA I–II; sinus rhythm; normal renal function; NT-proBNP <1000 pg/mL; no mid-wall fibrosis on CMR; LVEF recovery with GDMT. 5-year survival >85%.

Setting: GP-led monitoring with cardiology review every 6–12 months

Moderate Risk

Intermediate prognosis

LVEF 25–35%; NYHA II–III; persistent AF; renal impairment (eGFR 30–60); NT-proBNP 1000–5000 pg/mL; mid-wall LGE on CMR; incomplete response to GDMT after 6 months. 5-year survival 60–80%.

Setting: Heart failure specialist care, multidisciplinary HF clinic

High Risk

Poor prognosis — advanced therapies needed

LVEF <25%; NYHA III–IV despite optimal GDMT; LMNA or PLN or RBM20 pathogenic variant; progressive decline; recurrent hospitalisations; hyponatraemia; eGFR <30; NT-proBNP >5000 pg/mL; INTERMACS 1–4. 1-year mortality 25–50% without advanced therapy.

Setting: Urgent referral for heart transplant / LVAD evaluation

Prognostic Markers

Marker	Prognostic Significance	Action Threshold
NT-proBNP	Strongest independent predictor of mortality in HFrEF. Serial trajectory more important than single value.	Target <1000 pg/mL. Rising levels despite therapy indicate treatment failure or disease progression.
LVEF	Baseline LVEF and change with treatment predict outcomes. ≥10% absolute improvement confers survival benefit.	LVEF ≤35% after ≥3 months GDMT → ICD candidacy. Continued decline → advanced therapy referral.
CMR mid-wall fibrosis (LGE)	Presence of mid-wall LGE in DCM is an independent predictor of all-cause mortality, sudden death, and ventricular arrhythmias — OR 4.6 for combined events.	LGE-positive DCM: lower ICD implantation threshold; closer monitoring for arrhythmias.
Global longitudinal strain (GLS)	GLS >-8% (severely reduced) associated with worse outcomes. More sensitive than LVEF for early deterioration.	Serial GLS monitoring at echocardiography — decline >15% relative change warrants re-evaluation.
Renal function (eGFR)	Cardiorenal syndrome — progressive renal impairment predicts poor outcomes. Rapid decline (>20% over 3 months) is ominous.	eGFR <30 mL/min: reassess GDMT doses; consider advanced therapy referral.
Hyponatraemia	Serum sodium <135 mmol/L reflects neurohormonal activation and predicts mortality in acute and chronic HF.	Sodium <130 mmol/L: urgent HF specialist review; consider advanced therapies.
Genetic substrate	LMNA, PLN, RBM20 variants associated with worse prognosis (faster progression, arrhythmia risk, sudden death). TTNtv generally more benign.	High-risk genotype: ICD at lower LVEF threshold; earlier transplant listing consideration.
Exercise capacity (6MWT / CPET)	Peak VO₂ <12 mL/kg/min on cardiopulmonary exercise testing (CPET) indicates advanced HF and poor prognosis. 6-minute walk distance <300 m is also adverse.	Peak VO₂ <14 mL/kg/min: consider transplant listing. Peak VO₂ <12 mL/kg/min: strong indication.

Serial Monitoring Protocol

Baseline

Full echocardiography (LVEF, dimensions, GLS, diastolic function, MR). CMR if available. NT-proBNP. Full bloods (FBC, UEC, LFTs, iron studies, TFTs, HbA1c). ECG. Coronary assessment if indicated. Referral for genetic counselling.

2–4 weeks

Clinical review — symptoms, fluid status, blood pressure, heart rate. UEC + potassium (after RAASi/MRA initiation or uptitration). Assess tolerability and plan next GDMT titration step.

3 months

Repeat echocardiography (assess treatment response). NT-proBNP. UEC, eGFR, electrolytes. Symptom assessment (NYHA class). Decide on ICD candidacy if LVEF still ≤35%. Heart failure MDT review.

6 months

Reassess GDMT — is the patient at maximum tolerated doses? Repeat echo if LVEF was borderline at 3 months. Functional capacity assessment (6MWT or CPET if available). If no improvement → refer for advanced HF assessment.

Annually (ongoing)

Annual echocardiography. NT-proBNP (or 6-monthly if elevated). Bloods (UEC, eGFR, LFTs, iron studies, HbA1c). Symptom review and NYHA classification. Medication review — ensure all GDMT at optimal doses. Heart failure clinic follow-up.

Indications for Heart Transplant / LVAD Evaluation

🚨

Early referral is critical: Transplant referral should occur BEFORE the patient becomes critically unwell. The median waiting time for heart transplantation in Australia (via Transplant Australia / ANZOD) is 6–18 months. Patients who are too unwell at listing have worse post-transplant outcomes. Refer when patients are transitioning from INTERMACS 5–6 to 4.

Indication for Advanced Therapy Referral	Detail
Persistent NYHA III–IV despite optimal GDMT	Symptoms limiting daily activities after ≥3 months of maximally tolerated GDMT and device therapy (if indicated).
Recurrent HF hospitalisations	≥2 hospitalisations for acute decompensated heart failure within 12 months despite optimal outpatient therapy.
Declining peak VO₂	Peak VO₂ <14 mL/kg/min (or <50% predicted) on CPET. If <12 mL/kg/min — strong indication for transplant listing.
Progressive LVEF decline	Continued decline of LVEF despite uptitrated GDMT; LVEF <20% despite treatment.
Inotrope dependence	Requirement for continuous IV inotrope support (milrinone, dobutamine) as bridge to transplant or decision-making.
High-risk genotype with progressive phenotype	LMNA, PLN, or RBM20 with aggressive disease trajectory, recurrent VT/VF despite ICD, or rapid functional decline.
INTERMACS profiles 1–4	Profile 1 (crash and burn) through Profile 4 (resting symptoms) indicate need for urgent advanced therapies. LVAD as bridge to transplant or destination therapy.

Heart Transplantation in Australia

Approximately 100–130 heart transplants are performed annually in Australia and New Zealand through the ANZOD registry, with DCM as the primary diagnosis in ~45% of recipients.
Transplant centres: St Vincent's Hospital Sydney, Alfred Hospital Melbourne, Prince Charles Hospital Brisbane, Royal Adelaide Hospital, Fiona Stanley Hospital Perth, and Wellington Hospital (NZ).
1-year post-transplant survival exceeds 90% at Australian centres. Median graft survival is approximately 12–14 years.
Contraindications include active infection, active malignancy, severe irreversible pulmonary hypertension (PVR >6 Wood units despite vasodilator testing), active substance abuse, and severe psychosocial barriers to adherence.

Left Ventricular Assist Device (LVAD)

LVAD (HeartMate 3® is the current standard) is used as bridge to transplant (BTT), bridge to decision (BTD), or increasingly as destination therapy (DT) in patients ineligible for transplant.
Available at St Vincent's Hospital Sydney and Alfred Hospital Melbourne.
2-year survival with HeartMate 3 is approximately 75–80%. Stroke and device thrombosis rates have improved with contemporary devices.
Requires intensive anticoagulation management, driveline care, and specialist LVAD centre follow-up. Not all patients are suitable candidates — age, body habitus, and comorbidities are considered.

Recovery of LVEF — Can Therapy Be De-escalated?

⚠️

Do not stop GDMT in recovered DCM: Up to 20–30% of DCM patients may demonstrate LVEF recovery to ≥50% on GDMT. However, "recovered DCM" is NOT cured DCM. Discontinuation of GDMT frequently leads to LV relapse. Current evidence (TRED-HF trial) supports lifelong GDMT maintenance. ICD may be reconsidered if LVEF normalises, but this should only occur after detailed discussion with the patient and heart failure specialist. If LVEF has been normal for ≥6 months on full GDMT and there are no arrhythmias, ICD deactivation may be discussed in a shared decision-making framework.

Special Populations

🤰

Pregnancy

DCM in pregnancy encompasses pre-existing cardiomyopathy and peripartum cardiomyopathy (PPCM).
Contraindicated in pregnancy: ACEi, ARB, ARNI, SGLT2i, MRA — all are teratogenic. Must be stopped ideally before conception or immediately upon recognition of pregnancy.
Safe in pregnancy: Labetalol (200–1200 mg/day PO divided BD-TDS) or metoprolol (50–200 mg/day) for beta-blockade; hydralazine (25–75 mg PO TDS) + long-acting nitrate for afterload reduction; frusemide (use lowest effective dose — monitor amniotic fluid volume).
Women with LVEF <30% or NYHA III–IV should be counselled that pregnancy carries significant maternal risk (10–20% mortality in severe DCM). Multidisciplinary cardio-obstetric team management at a tertiary centre is essential.
Mode of delivery: vaginal delivery preferred with assisted second stage (instrumental); caesarean section for obstetric indications or haemodynamic instability.
Bromocriptine (2.5 mg PO BD for 2 weeks then daily for 4 weeks) may be considered in PPCM — small studies suggest improved recovery. Avoid breastfeeding if using bromocriptine.
Brestfeeding: ACEi/ARB are compatible with breastfeeding. Enalapril is preferred. SGLT2i: avoid breastfeeding (limited data). Beta-blockers: propranolol and metoprolol are compatible.

👶

Paediatric DCM

DCM is the most common cardiomyopathy in children (~50–60% of paediatric cardiomyopathies). Incidence: 0.57–1.24 per 100,000 children per year (Australian data).
Aetiology differs from adults: idiopathic (~50%), myocarditis (~15%), neuromuscular disease (Duchenne/Becker), metabolic/inborn errors of metabolism, and genetic/familial (~25%).
Age at presentation matters: infants <1 year have higher rates of myocarditis and metabolic aetiology; older children more often have genetic or idiopathic causes.
GDMT adaptation: Enalapril (0.1 mg/kg PO BD, titrate to 0.5 mg/kg BD) — standard paediatric ACEi. Carvedilol (0.05 mg/kg PO BD, titrate to 0.4 mg/kg BD) — limited paediatric RCT evidence but used in Australian paediatric HF centres. SGLT2i: NOT approved for paediatric use in heart failure.
Spironolactone: 1–2 mg/kg/day PO. Frusemide: 0.5–2 mg/kg/day PO.
ICD in children: indicated for secondary prevention or high-risk primary prevention (LMNA with significant conduction disease). Primary prevention ICD in children is challenging due to size constraints — subcutaneous ICD may be considered in older children.
Referral to paediatric cardiology at a tertiary centre (e.g., Royal Children's Hospital Melbourne, Children's Hospital Westmead, Queensland Children's Hospital) for all newly diagnosed cases.
Genetic testing is particularly valuable in paediatric DCM — high yield for pathogenic variants, especially if diagnosed <1 year of age.

👴

Elderly

DCM in the elderly (≥75 years) is often multifactorial — age-related myocardial remodelling, long-standing hypertension, ischaemic heart disease, and tachycardia-mediated cardiomyopathy from AF all contribute.
GDMT initiation requires careful dose adjustment and monitoring — start at lowest doses and titrate slowly. Hypotension and renal impairment are common barriers.
Polypharmacy: review all medications for interactions and deprescribe where appropriate. Avoid NSAIDs which worsen fluid retention and renal function.
ICD decision-making: balance life expectancy and comorbidities. Patients with limited life expectancy (<1 year) or severe frailty may not benefit from primary prevention ICD.
Frailty assessment (Clinical Frailty Scale) should inform treatment intensity and advance care planning. Shared decision-making is particularly important.
Heart failure management programs and TeleHF monitoring (available through state health services) can reduce emergency presentations and support community-based care.

🫘

Renal Impairment

Cardiorenal syndrome is common in DCM — worsening renal function reflects low cardiac output and venous congestion, and independently predicts mortality.
ACEi/ARB/ARNI: Use with caution if eGFR <30 mL/min. Avoid if eGFR <20. Monitor K⁺ and creatinine within 1–2 weeks of initiation or dose change. Accept up to 30% rise in creatinine — do not discontinue unless K⁺ >6.0 or acute kidney injury.
MRA: Avoid if eGFR <30 or K⁺ >5.0. Higher hyperkalaemia risk when combined with ARNI.
SGLT2i: Can initiate if eGFR ≥20 mL/min for heart failure indication (dapagliflozin PBS requires eGFR ≥25). The diuretic effect may reduce loop diuretic requirements.
Diuretics: May need higher doses or combination (frusemide + metolazone) in advanced renal impairment. Monitor volume status and renal function weekly during titration.
Haemodialysis patients with DCM: management is complex and requires nephrology-cardiology co-management. Ultrafiltration targets and dry weight optimization are key.

🫁

Hepatic Impairment

Congestive hepatopathy is common in advanced DCM — hepatic congestion leads to elevated LFTs (typically AST/ALT 2–3× normal, raised ALP/GGT). Cardiac cirrhosis may develop with chronic right heart failure.
ACEi/ARB: use with caution in hepatic impairment — enalapril does not require hepatic dose adjustment. Sacubitril/valsartan: limited data in severe hepatic impairment (Child-Pugh C); use with caution.
Spironolactone: may accumulate in hepatic impairment — start at lowest dose and monitor closely. Eplerenone: avoid if Child-Pugh C.
Carvedilol: extensively hepatically metabolised — use cautiously; consider dose reduction in significant hepatic impairment.
Warfarin (if indicated for AF): requires careful INR monitoring — increased sensitivity in hepatic congestion.

🛡️

Immunocompromised

HIV-associated cardiomyopathy: DCM occurs in 10–15% of people living with HIV (PLWH), mediated by direct viral myocardial injury, chronic inflammation, antiretroviral toxicity, and opportunistic infections. Echocardiographic screening is recommended for PLWH with new cardiac symptoms.
Treatment: GDMT applies. Optimise antiretroviral therapy. Consider EMB to exclude specific opportunistic causes (Toxoplasma, CMV, Cryptococcus) if immunosuppressed with acute cardiomyopathy.
Transplant candidates: HIV-positive patients can undergo heart transplantation with good outcomes if viral load is undetectable and CD4 count >200 cells/µL on stable ART.
Post-transplant immunosuppression: standard regimens (tacrolimus + mycophenolate + prednisolone) are used with close HIV virological monitoring. Drug interactions between calcineurin inhibitors and protease inhibitors require careful dose adjustment.
Immune checkpoint inhibitor (ICI) cardiomyopathy: increasingly recognised in oncology patients. Prompt cessation of ICI and urgent cardiology referral for immunosuppression. See Treatment Protocols section for management.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of cardiovascular disease and heart failure. Culturally safe, evidence-based approaches to DCM management are essential to reduce health inequity and improve outcomes.

Disease Burden

Aboriginal and Torres Strait Islander Australians have a 2–3-fold higher rate of heart failure hospitalisation compared to non-Indigenous Australians (AIHW 2023). Cardiomyopathy — both primary and secondary (to rheumatic heart disease, rheumatic fever, and ischaemic heart disease) — contributes significantly to this excess burden. Heart failure mortality rates are approximately 1.5–2 times higher in ATSI populations, with earlier age of onset (mean age at diagnosis ~55 years vs ~70 years in non-Indigenous Australians).

Rheumatic Heart Disease (RHD) — A Key Cause of Secondary DCM

RHD remains endemic in remote Aboriginal communities in the Northern Territory, northern Western Australia, and northern Queensland. Approximately 6,000 Australians live with RHD, with >90% being Aboriginal and Torres Strait Islander peoples. Chronic rheumatic carditis leads to progressive valvular disease and secondary ventricular dilatation, mimicking or contributing to DCM. The RHD Endgame Strategy (2020–2031) aims to eliminate RHD as a public health problem. All ATSI patients with newly diagnosed DCM in endemic regions should have RHD excluded with echocardiography.

Geographic and Service Access Barriers

Many Aboriginal and Torres Strait Islander Australians live in remote or very remote areas where specialist cardiology services, echocardiography, and advanced diagnostics (CMR, genetic testing) are unavailable. Access to GDMT may be delayed. Telehealth cardiac services (including the NT Cardiac telehealth program and RFDS-supported outreach) are critical for bridging this gap. Where possible, echocardiography should be performed during specialist outreach visits or via portable handheld devices.

Culturally Safe Care

Cultural safety is fundamental to effective DCM management in ATSI communities. This includes: acknowledging and respecting Indigenous health beliefs; engaging Aboriginal and Torres Strait Islander health workers and liaison officers in care delivery; using plain language and culturally appropriate health education resources; incorporating family-centred and community-based approaches; understanding the role of "sorry business" and cultural obligations that may affect appointment attendance; and supporting continuity of care through Aboriginal Community Controlled Health Organisations (ACCHOs).

Risk Factor Profile

ATSI Australians have higher prevalence of modifiable risk factors for DCM: smoking (40% vs 11% nationally), diabetes (type 2 diabetes prevalence ~3× higher), obesity, rheumatic fever history, harmful alcohol use, and chronic kidney disease. These factors accelerate myocardial dysfunction and complicate GDMT management. Integrated chronic disease management programs within ACCHOs are the optimal model for addressing these co-morbidities alongside DCM care.

Genetic Considerations

Genetic cardiomyopathies are likely underdiagnosed in ATSI populations due to limited access to genetic testing and counselling. There may be population-specific genetic variants that are not well-represented in current reference databases. Genetic testing should be offered on the same basis as non-Indigenous patients, with testing facilitated through state genetics services. Telehealth genetic counselling can improve access for remote communities.

Medication Access and PBS

PBS Closing the Gap (CTG) co-payment measure: eligible ATSI patients can access PBS medicines at a reduced co-payment through their Aboriginal health service or community pharmacy. This is critical for ensuring adherence to GDMT, which requires multiple concurrent medications. Remote Area Aboriginal Health Services can supply medicines under Section 100 of the National Health Act, ensuring availability where local pharmacies are not accessible. Medication adherence may be supported by blister packing through community pharmacies and health worker-supervised medication management.

Transplant and Advanced Therapies

ATSI Australians are underrepresented on the heart transplant waiting list relative to their disease burden. Barriers include late referral, distance from transplant centres, psychosocial factors, and historically poorer post-transplant outcomes in some series (related to late presentation and comorbidity burden). Proactive early referral for advanced HF assessment, support for relocation during transplant workup, and culturally safe post-transplant care pathways are needed to address this inequity.

📚 References

1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–e1032.
2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
3. Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association. Circulation. 2016;134(23):e579–e646.
4. > Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet. 2017;390(10092):400–414.
5. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281–302.
6. Verdonschot JAJ, Hazebroek MR, Derks KWJ, et al. Titin cardiomyopathy phenotype varies with titin variant type. J Am Coll Cardiol. 2018;72(17):2053–2054.
7. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2016;37(23):1850–1858.
8. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61–73.
9. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648.
10. Australian Institute of Health and Welfare. Heart, stroke and vascular disease — Australian facts. AIHW, Canberra; 2023.
11. Australian Commission on Safety and Quality in Health Care. Chronic Heart Failure Clinical Care Standard. ACSQHC, Sydney; 2024.
12. RHDAustralia (ARF/RHD writing group). National guideline for the prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
13. Gulati G, Japp AG, Raza S, et al. Absence of myocardial fibrosis predicts favourable long-term survival in new-onset heart failure. Circ Cardiovasc Imaging. 2018;11(3):e007250.
14. > Januzzi JL Jr, Butler J, Zannad F, et al. Prognostic importance of NT-proBNP trajectory on sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction. JACC Heart Fail. 2021;9(11):814–824.
15. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129–2200.
16. Crespo-Leiro MG, Costanzo MR, Gustafsson F, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505–1535.
17. Sahni S, Abegaz B, Brown NJ. Peripartum cardiomyopathy: a review. Aust N Z J Obstet Gynaecol. 2023;63(1):17–26.
18. Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS). ANZSCTS Cardiac Surgery Database Project — Heart Transplant Report. Melbourne; 2023.
19. James PA, Semsarian C. Sudden cardiac death in the young: the increasing role of genetic testing. Med J Aust. 2023;218(7):303–309.
20. Semsarian C, Ingles J. Genetic testing in cardiomyopathies — practical considerations for the clinician. Heart Lung Circ. 2022;31(1):23–30.